Having trouble viewing this email? View in your browser.
ESCMID Logo

17 July 2018
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,

ESCMID Executive Office.

 

ESCMID remembers colleague and friend Prof. Mark E. Shirtliff, PhD, FESCMID.

We at ESCMID were greatly saddened  to learn that Mark E. Shirtliff, Professor at the University of Maryland-Baltimore, had lost his life in a rafting accident on the Yellowstone River near Gardiner, Montana on July 12, 2018.

He was a leading expert in bacterial pathogenesis and biofilms, and was a regular contributor on this topic as a member of faculty for many ECCMID congresses. He served as member of Programme Committee for three ECCMIDs (2016-2018). This outstanding contribution was recognised with Shirtliff being awarded the title of ESCMID Fellow. This is a title appointed personally by the ESCMID Executive Committee to members that excel in their field.

Most of all, we will remember his abundant energy and infectious sense of humour. Shirtliff was a great team player and would often be seen at ECCMID and other meetings, sharing a laugh with smiling colleagues.

We send our sincerest condolences to his wife and four children in Baltimore, Maryland.

› Read more
 

ESCMID AMR: Bench to practice, Havana, Cuba

Make sure to enrol in the ESCMID International Conference on Antimicrobial Resistance: From bench to practice, taking place in Havana, Cuba, from 26-27 September, 2018.

ESCMID is offering attendance grants to young scientist members interested in attending. To apply, send a 100-word motivational statement to cubaconf2018@escmid.org along with your proof of membership.

› Read more
 

ESCMID Postgraduate Course on Infection in the Elderly

The ESCMID Postgraduate Course Infection in the Elderly: the Next Challenges is approaching in Grenoble, France. Don’t miss out on expert and engaging presentations in this rapidly evolving area of infectious disease medicine.

› Read more
 

Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect

Isavuconazole is a triazole indicated for the treatment of invasive aspergillosis and mucormicosis. Marcos-Zambrano and colleagues performed antifungal susceptibility testing on 762 isolates causing fungaemia in patients; they used isavuconazole concentration ranging from 0.002 to 8 mg/L and measured trailing observing residual growth. C. albicans showed the highest in vitro susceptibility to isavuconazole (0.03 mg/L) followed by C. parapsilosis, and C. tropicalis, C. Glabrata and C. krusei. Concerning residual growth, more than a half of C. glabrata isolates classified as heavy trailers, most C. tropicalis isolates were slight or moderate trailers and the majority of C. Parapsilosis and C. Krusei isolates were classified as residual trailers. C. albicans proved potential to show isavuconazole trailing with up to 67.5% of isolates classified as moderate or heavy trailers.

› Read more
 

Predictive accuracy for outcomes of ventilator-associated events in critically ill children and adults

The ESCMID Study Group for Infections in Critically Ill Patients (ESGCIP) is glad to announce the publication of two papers funded by ESCMID with a Study Group Research Grant of 30’000 euros. In these two papers, authors evaluated the predictive accuracy for outcomes of ventilator-associated events in critically ill children and adults. Peña-López and colleagues focused on a cohort of children and compared outcome-predicting algorithms based on surveillance definitions of the Center for Disease Control and Prevention (2008 and 2013) with a new algorithm (Ped-VAE) developed specifically for children. Ramírez‑Estrada and colleagues studied instead a cohort of 244 adult patients.

Assessing prediction accuracy for outcomes of ventilator-associated events and infections in critically ill children: a prospective cohort study. Peña-López et al., CMI 2018, Volume 24, Issue 7, Pages 732–737

Assessing predictive accuracy for outcomes of ventilator-associated events in an international cohort: the EUVAE study. Ramírez‑Estrada et al., Intensive Care Med, 2018

› Read more
 

Variability in contact precautions to control the nosocomial spread of multi-drug resistant organisms in the endemic setting: a multinational cross-sectional survey

The ESCMID Study Group for nosocomial infections (ESGNI) played an important role in this study by Gysin et al., recently published in BMC. The authors wanted to explore the diversity in adopting contact precaution and isolation practices for gram-positive and gram-negative multidrug-resistant organisms, and to assess barriers to their implementation. ESGNI was involved in the design of the survey and in spreading it at ECCMID 2014. 213 respondents from most European countries and from a large number of non-EU countries across Africa, Asia, and South America filled in the survey. The results confirmed that indications and practical implementation of contact precautions including isolation measures vary considerably. Major inconsistencies exist in the handling of extended-spectrum-beta-lactamase-producing enterobacteriaceae, carbapenem-resistant E. coli, and carbapenem-resistant enterobacteriaceae. The inability to separate patients is due to the lack of personnel and insufficient single rooms, rather than a consequence of guideline scepticism or evidence-base paucity.

This study is published open access.

› Read more
 

Fellowship opportunity: 10 post-doctoral clinician scientists positions

BITRECS Biomedicine international training research programme for excellent clinician-scientists is a fellowship programme co-funded by the European Commission. BITRECS is seeking to recruit excellent and highly motivated clinician-scientists to boost their research careers; a call for 10 positions is currently open until 30 September 2018. The successful postdoctoral researchers may carry out their 3-year research placement through one of the following schemes: 1) Outgoing scheme: 12-18 month outgoing phase in any country worldwide different from Spain and 18-24 month at IDIBAPS and 2) Incoming scheme: 36 months at IDIBAPS, the Institut d’Investigacions Biomèdiques August Pi i Sunyer in Barcelona, Catalonia, Spain.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.